Getting sepsis therapy right: Is decreasing inflammation or increasing the host immune response the better approach?

Science

Volumn 347, Issue 6227, 2015, Pages 1201-1202

  Hotchkiss, Richard S ^a   Sherwood, Edward R ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 3; IL3 PROTEIN, HUMAN;

IMMUNE RESPONSE;

ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; HEMATOPOIETIC CELL; HOST; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFLAMMATION; LYMPHOCYTE; MESENCHYMAL STEM CELL; MONOCYTE; NONHUMAN; ORGAN INJURY; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; SEPSIS; ANIMAL; BLOOD; IMMUNOLOGY;

ANIMALS; HUMANS; INTERLEUKIN-3; SEPSIS;

EID: 84924777962     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aaa8334     Document Type: Article

References (15)

1. V. Liu et al., JAMA 312, 90 (2014).
2. R. S. Hotchkiss, I. E. Karl, N. Engl. J. Med. 348, 138 (2003).
3. J. Cohen et al., Lancet Infect. Dis. 12, 503 (2012).
4. D. C. Angus, JAMA 306, 2614 (2011).
5. G. F. Weber et al., Science 347, 1260 (2015).
6. K. Németh et al., Nat. Med. 15, 42 (2009).
7. C. Meisel et al., Am. J. Respir. Crit. Care Med. 180, 640 (2009).
8. R. S. Hotchkiss et al., Lancet Infect. Dis. 13, 260 (2013).
9. F. Venet et al., J. Immunol. 189, 10 (2012).
10. G. S. Martin, D. M. Mannino, M. Moss, Crit. Care Med. 34, 15 (2006).
11. J. Leentjens et al., Am. J. Respir. Crit. Care Med. 187, 1287 (2013).
12. J. S. Boomer et al., JAMA 306, 2594 (2011).
13. G. P. Otto et al., Crit. Care 15, R183 (2011).
14. A. H. Walton et al., PLOS ONE 9, e98819 (2014).
15. J. L. Vincent, L. Teixeira, Am. J. Respir. Crit. Care Med. 190, 1081 (2014).